Celebrex Shows Benefit In First-of-Its-Kind Lung Cancer Chemoprevention Trial

Celecoxib, the anti-inflammatory medication also known by the trade name Celebrex, has proven to be safe and reduces a specific proliferation measurement of precancerous lesions in the lung, according to a study from The University of Texas M. D. Anderson Cancer Center. This finding demonstrates the significance of COX-2 inhibition toward preventing lung cancer in individuals at higher risk of developing the disease.

More: continued here

Filed under: Clinical Trials on May 17th, 2008